Alex J. Vecchio

Summary: Tight junctions are dynamic membrane-bound protein assemblies that maintain barrier function for tissues as cells divide, grow, and move through development and throughout life. Maintenance of tissue barriers requires spatially separated intracellular and extracellular signaling pathways to be linked through novel and dynamic protein interaction networks. Tight junction intracellular signaling is governed by zona occludens-1 (ZO-1), a Membrane-Associated GUanylate Kinase (MAGUK) family protein that recruits and assembles transmembrane proteins and scaffolds them to the actin cytoskeleton through its own oligomerization, localization to membranes, and phase separation. Here we report comprehensive quantitative studies that nearly completely maps the intracellular interaction network between ZO-1 and tight junction transmembrane proteins that elucidates the biophysical principles governing their binding and a mechanism for how stimuli transmit through membranes. We establish where, how, and with whom each protein interacts, and identify how membrane proteins enable ZO-1 and greater tight junction function through specific interactions or by phase separation. Our findings reveal the intracellular interactome that triggers and regulates tight junction assembly, the active and direct roles each membrane protein plays in these processes, and provide a mechanism for how intra/extracellular signaling is coupled to transmit mechanochemical signals between cells via tight junctions. These insights provide a prospective blueprint for how other MAGUK/membrane protein interaction networks form and function across biology.

Claudins regulate molecular transport between cells via the paracellular route at tight junctions in epithelial and endothelial tissues and are prime targets for biologic therapies. Claudin–claudin interactions through their extracellular segments facilitate form and function of tight junction barriers, making for defined targetable surfaces. However, developing biologic or small molecule binders against claudin extracellular segments is challenging because they are small, dynamic, and no structures of assemblies exist to guide efforts to rationally design binders. Here, I review claudin targeting strategies, recent advances using natural and synthetic molecules, and the impact these molecules have had on claudin or tight junction biology. I surmise that the therapeutic promise of any molecule is dependent on deeply considering how claudins assemble and what structures they take within and outside of tight junctions. This review thus focuses on structure‐forward themes, with the hope of providing a framework for researchers to apply this knowledge in the design and development of new claudin‐binding molecules with diverse properties, mechanisms, and functions.

Clostridium perfringens enterotoxin (CpE) causes cytotoxic gastrointestinal disease in mammalian epithelium by binding membrane protein receptors called claudins. Claudins direct the formation of cell/cell tight junctions through oligomerization and govern the transport of molecules between individual cells. CpE binds claudins through its C‐terminal domain (cCpE) and induces cytotoxicity through its N‐terminal domain. The non‐toxic cCpE is a useful tool to study claudins, tight junctions, and for translational applications, such as increasing the permeability of restrictive tissues like the blood–brain barrier or selective targeting of claudin overexpressing cancers. Conversely, there are no specialized molecular tools to study CpE or cCpE, or to modulate or inhibit their functions. We previously reported the development of synthetic antigen‐binding fragments (sFabs) that bind cCpE, and low‐resolution structures of them bound to claudin/cCpE complexes. Here, we determine high‐resolution structures of sFab COP‐2 bound to cCpE using X‐ray crystallography and cryogenic electron microscopy. The structures and biophysical findings provide the mechanism of COP‐2 binding to cCpE and the molecular determinants driving their interactions. These insights can advance the design of new antibody‐based tools from our COP‐2 scaffold to study or alter cCpE function and give rise to a “Trojan horse” strategy that exploits cCpE's tight junction barrier disrupting function to selectively deliver conjugated therapeutics through normally impermeable tissues.

Protein–protein interactions are at the core of all key biological processes. However, the complexity of the structural features that determine protein–protein interactions makes their design challenging. Here we present BindCraft, an open-source and automated pipeline for de novo protein binder design with experimental success rates of 10–100%. BindCraft leverages the weights of AlphaFold2 (ref. ¹) to generate binders with nanomolar affinity without the need for high-throughput screening or experimental optimization, even in the absence of known binding sites. We successfully designed binders against a diverse set of challenging targets, including cell-surface receptors, common allergens, de novo designed proteins and multi-domain nucleases, such as CRISPR–Cas9. We showcase the functional and therapeutic potential of designed binders by reducing IgE binding to birch allergen in patient-derived samples, modulating Cas9 gene editing activity and reducing the cytotoxicity of a foodborne bacterial enterotoxin. Last, we use cell-surface-receptor-specific binders to redirect adeno-associated virus capsids for targeted gene delivery. This work represents a significant advancement towards a ‘one design-one binder’ approach in computational design, with immense potential in therapeutics, diagnostics and biotechnology.

Claudins are a 27-member family of membrane proteins that form and fortify specialized cell contacts in endothelium and epithelium called tight junctions. Tight junctions restrict paracellular transport through tissues by forming molecular barriers between cells. Claudin-binding molecules thus hold promise for modulating tight junction permeability to deliver drugs or as therapeutics to treat tight junction–linked disease. The development of claudin-binding molecules, however, is hindered by their physicochemical intractability and small targetable surfaces. Here, we determine that a synthetic antibody fragment (sFab) that we developed binds with nanomolar affinity directly to 10 claudin subtypes and other distantly related claudin family members but not to other tight junction–localized membrane proteins. It does so by targeting the extracellular surfaces of claudins, which we verify by applying this sFab to a model intestinal epithelium and observe that it opens paracellular barriers comparable to a known, but application limited, tight junction modulating protein. This pan-claudin-binding molecule holds potential for both basic and translational applications as it is a probe of claudin and tight junction structure in vitro and in vivo and a tool to modulate the permeability of tight junctions broadly across tissue barriers.

Claudins are a 27-member protein family that form and fortify specialized cell contacts in endothelium and epithelium called tight junctions. Tight junctions restrict paracellular transport across tissues by forming molecular barriers between cells. Claudin-binding molecules thus hold promise for modulating tight junction permeability to deliver drugs or as therapeutics to treat tight junction-linked disease. The development of claudin-binding molecules, however, is hindered by their intractability and small targetable surfaces. Here, we determine that a synthetic antibody fragment (sFab) we developed binds directly to 10 claudin subtypes with nanomolar affinity by targeting claudin’s paracellular-exposed surface. Application of this sFab to cells that model intestinal epithelium show that it opens the paracellular barrier comparable to a known, but application limited, tight junction modulator. This novel pan-claudin-binding molecule can probe claudin or tight junction structure and holds potential as a broad modulator of tight junction permeability for basic or translational applications.

Pathogenic strains of Clostridium perfringens secrete an enterotoxin (CpE) that causes prevalent, severe, and sometimes deadly gastrointestinal disorders in humans and domesticated animals. CpE binds selectively to membrane protein receptors called claudins on the apical surfaces of small intestinal epithelium. Claudins normally construct tight junctions that regulate epithelial paracellular transport but are hijacked from doing so by CpE and are instead led to form claudin/CpE “small complexes”. Small complexes are building blocks for assembling oligomeric β-barrel pores that penetrate the plasma membrane and induce gut cytotoxicity. Here we present structures of CpE in complexes with its native claudin receptor in humans, claudin-4, at 4.0 and 2.8 Å using cryogenic electron microscopy. The structures reveal the overall architecture of the small complex, that the small complex can be kinetically trapped, and resolve its key features; like the residues used in claudin/CpE complex binding, the orientation of CpE relative to the membrane, and CpE-induced structural changes to claudin-4. Further, the structures allude to the biophysical procession from small complex to cytotoxic β-barrel pore used by CpE during pathogenesis and the role of trypsin in this process. In full, this work elucidates the structure and mechanism of claudin-bound CpE pore assembly and provides strategies to obstruct its formation to treat CpE-induced gastrointestinal diseases.

De novo design of complex protein folds using solely computational means remains a substantial challenge¹. Here we use a robust deep learning pipeline to design complex folds and soluble analogues of integral membrane proteins. Unique membrane topologies, such as those from G-protein-coupled receptors², are not found in the soluble proteome, and we demonstrate that their structural features can be recapitulated in solution. Biophysical analyses demonstrate the high thermal stability of the designs, and experimental structures show remarkable design accuracy. The soluble analogues were functionalized with native structural motifs, as a proof of concept for bringing membrane protein functions to the soluble proteome, potentially enabling new approaches in drug discovery. In summary, we have designed complex protein topologies and enriched them with functionalities from membrane proteins, with high experimental success rates, leading to a de facto expansion of the functional soluble fold space.

Claudins are a 27-member family of ~25 kDa membrane proteins that integrate into tight junctions to form molecular barriers at the paracellular spaces between endothelial and epithelial cells. As the backbone of tight junction structure and function, claudins are attractive targets for modulating tissue permeability to deliver drugs or treat disease. However, structures of claudins are limited due to their small sizes and physicochemical properties—these traits also make therapy development a challenge. Here we report the development of a synthetic antibody fragment (sFab) that binds human claudin-4 and the determination of a high-resolution structure of it bound to claudin-4/enterotoxin complexes using cryogenic electron microscopy. Structural and biophysical results reveal this sFabs mechanism of select binding to human claudin-4 over other homologous claudins and establish the ability of sFabs to bind hard-to-target claudins to probe tight junction structure and function. The findings provide a framework for tight junction modulation by sFabs for tissue-selective therapies.